Activation of RAS Family Genes in Urothelial Carcinoma
- 1 May 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 181 (5), 2312-2319
- https://doi.org/10.1016/j.juro.2009.01.011
Abstract
Purpose: Bladder cancer is the fifth most common malignancy in men in Western society. We determined RAS codon 12 and 13 point mutations and evaluated mRNA expression levels in transitional cell carcinoma cases. Materials and Methods: Samples from 30 human bladder cancers and 30 normal tissues were analyzed by polymerase chain reaction/restriction fragment length polymorphism and direct sequencing to determine the occurrence of mutations in codons 12 and 13 of RAS family genes. Moreover, we used real-time reverse transcriptase-polymerase chain reaction to evaluate the expression profile of RAS genes in bladder cancer specimens compared to that in adjacent normal tissues. Results: Overall H- RAS mutations in codon 12 were observed in 9 tumor samples (30%). Two of the 9 patients (22%) had invasive bladder cancer and 7 (77%) had noninvasive bladder cancer. One H- RAS mutation (11%) was homozygous and the remaining 89% were heterozygous. All samples were WT for K and N- RAS oncogenes. Moreover, 23 of 30 samples (77%) showed over expression in at least 1 RAS family gene compared to adjacent normal tissue. K and N- RAS had the highest levels of over expression in bladder cancer specimens (50%), whereas 27% of transitional cell carcinomas demonstrated H- RAS over expression relative to paired normal tissues. Conclusions: Our results underline the importance of H- RAS activation in human bladder cancer by codon 12 mutations. Moreover, they provide evidence that increased expression of all 3 RAS genes is a common event in bladder cancer that is associated with disease development.Keywords
This publication has 15 references indexed in Scilit:
- The Staging of Cancer: A Retrospective and Prospective AppraisalCA: A Cancer Journal for Clinicians, 2008
- Non-Invasive Urothelial Neoplasms: According to the Most Recent WHO ClassificationEuropean Urology, 2004
- Screening of H-ras Gene Point Mutations in 50 Cases of Bladder CarcinomaInternational Journal of Urology, 1997
- Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumorsCancer Letters, 1996
- Identification of H-ras Mutations in Urine Sediments Complements Cytology in the Detection of Bladder TumorsJNCI Journal of the National Cancer Institute, 1995
- Screening of human bladder tumors and urine sediments for the presence of H‐ras mutationsInternational Journal of Cancer, 1993
- Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cellsCancer, 1993
- An Association between the Risk of Cancer and Mutations in the HRAS1 Minisatellite LocusNew England Journal of Medicine, 1993
- ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma.The Journal of Experimental Medicine, 1985
- Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologueNature, 1983